Dr Reddy reported three FDA observations before Dr Reddy stock results

Published on 10/19/2026 at 09:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Dr Reddy disclosed three FDA observations at FTO-9 on October 14, 2026. Dr Reddy stock heads to October 23 results after Q1 revenue fell 6.00 percent.

Regulatory review and earnings

Dr Reddy reported three FTO-9 observations on October 14, 2026.
Q1 net profit fell 69.00 percent year over year.
Dr Reddy stock traded at INR 1,234.90 on October 19, 2026.

Dr Reddy stock, pharmaceuticals, FDA inspection, quarterly results, NSE, Illustration mit AI erstellt.

Dr Reddy reported three US Food and Drug Administration observations at its FTO-9 manufacturing facility in Visakhapatnam after an inspection on October 8 and October 9, 2026, according to StockTitan. The company said it would address the findings within the stipulated timeline.

Three inspections shaped October

The recent regulatory sequence has produced three dated markers. On October 7, 2026, Dr. Reddy's announced that it would publish second-quarter and first-half results on October 23, according to FinancialFilings. From October 8 to October 9, the FTO-9 inspection ended with three observations, as reported in the StockTitan filing. On October 14, 2026, the company filed the inspection outcome, making the three observations the latest dated event in this sequence.

What does the filing mean for earnings?

The regulatory update arrives against a weak first quarter. The Economic Times reported that revenue from operations fell 6.00 percent year over year to INR 8,071 crore in the first quarter of fiscal year 2027, while net profit dropped 69.00 percent to INR 443 crore. The report also identified an INR 240 crore semaglutide API-related impact, including inventory provisions. Those figures give the October 23 results a clear test: management must show how regulatory remediation and product issues affect the recovery path.

October 23 sets the next checkpoint

The next substantiated date is October 23, 2026, when Dr. Reddy's is scheduled to release results for the quarter and six months ended September 30, 2026, followed by an earnings call at 10:00 a.m. ET, according to FinancialFilings. The reporting period will show whether the company can stabilize revenue after the first-quarter decline.

Stock context stays in rupees

On the NSE, Dr Reddy stock was trading at INR 1,234.90 on October 19, 2026 at 1:05 p.m. IST. The same quotation showed a 52-week range of INR 1,101.00 to INR 1,414.90 and a market capitalization of INR 1.0 trillion.